{
    "clinical_study": {
        "@rank": "24956", 
        "brief_summary": {
            "textblock": "Chronic hepatitis B virus infection is an important cause of morbidity and mortality.\n      Tenofovir disoproxil fumarate and entecavir were licensed for the treatment of hepatitis B\n      virus infection. In this study, the investigators will try to make comparison between\n      Entecavir and Tenofovir and investigate the efficacy."
        }, 
        "brief_title": "Comparison of the Efficacy of Entecavir and Tenofovir Monotherapy for the Treatment of Nucleos(t)Ide-na\u00efve Patients With Chronic Hepatitis B in Korea", 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 < Age < 70\n\n          -  HBV DNA > 100,000 copies/mL and increased ALT over 2 times compared with normal range\n             if HBsAg (+), HBeAg (+)\n\n          -  HBV DNA > 10,000 copies/mL and increased ALT compared with normal range if HBsAg (+),\n             HBeAg (-)\n\n        Exclusion Criteria:\n\n          -  With HCV  or other liver disease\n\n          -  With kidney disease\n\n          -  decompensated liver cirrhosis\n\n          -  with hepatocellular carcinoma\n\n          -  refuse this clinical trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "treatment of nucleos(t)ide-naive patients who were diagnosed with chronic hepatitis B in\n        Korea"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776814", 
            "org_study_id": "GAIRB2963-2012"
        }, 
        "intervention_browse": {
            "mesh_term": "Tenofovir"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Entecair", 
            "Tenofovir"
        ], 
        "lastchanged_date": "January 25, 2013", 
        "location": {
            "contact": {
                "email": "joojoomj@gilhospital.com", 
                "last_name": "Ju Seung Kim, Fellow", 
                "phone": "+82 +32 460 2792"
            }, 
            "facility": {
                "address": {
                    "city": "Incheon", 
                    "country": "Korea, Republic of", 
                    "zip": "405-760"
                }, 
                "name": "Gachon University Gil Medical Center, Department of Gastroenterology"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "joojoomj@gilhospital.com", 
            "last_name": "Ju Seung Kim, Fellow", 
            "phone": "+80+32 460 2792"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will check the HBV DNA level at 3, 6, 9, 12 months after taking entecavir and tenofovir", 
            "measure": "virologic response", 
            "safety_issue": "Yes", 
            "time_frame": "changes from baseline HBV DNA level at 3, 6, 9, 12 months after taking entecavir or tenofovir"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776814"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Gachon University Gil Medical Center", 
            "investigator_full_name": "Ju Seung Kim, MD", 
            "investigator_title": "principle investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Patients will check the level of alanine transaminasel at 3, 6, 9, 12 months after taking entecavir and tenofovir", 
            "measure": "reduction of alanine transaminase", 
            "safety_issue": "Yes", 
            "time_frame": "changes from baseline ALT level at 3,6,9,12 months after taking entecavir or tenofovir"
        }, 
        "source": "Gachon University Gil Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gachon University Gil Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}